Acrux logo

Acrux(ASX) ACR

Market CapA$6.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-98%
5 Year-92%
1 Year-21%
1 Month+0%
A$0.01
+10.00%
+0.00Today
Acrux last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-09
Acrux stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10%AUD 0.012026-10-02
1 month+0%AUD 0.012026-09-09
3 month+0%AUD 0.012026-07-08
Year to date-26.67%AUD 0.022025-12-31
1 year-21.43%AUD 0.012025-10-09
3 year-73.17%AUD 0.042023-10-10
5 year-91.54%AUD 0.132021-10-08
Since inception-98.32%AUD 0.592004-09-29

Acrux Financials at a Glance

Market Cap

A$6.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.83M

Net Income (TTM)

-A$6.55M

EPS (TTM)

-A$0.00

P/E Ratio

-7.86

Dividend

A$0.00

Beta (Volatility)

-0.09 (Low)

Price

A$0.01

Volume

752,158

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.02

Estimated Earnings Date

Mar 2, 2027

ACR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acrux

Acrux Limited specializes in the development and commercialization of generic and topically applied pharmaceutical products. The company operates globally, providing a range of testosterone therapies and estradiol sprays for various medical needs.

Products and Services
  • Testosterone therapies including oral tablets and transdermal patches
  • Estradiol sprays marketed as Evamist and Lenzetto
  • Innovative delivery systems for hormone replacement therapies
Growth Outlook
  • Recent quarterly revenue increased to AUD 2.9 million, showing strong demand
  • Gross profit margin improved to 92.6% in the latest quarter
  • Expansion into international markets is underway, enhancing growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 10.5 million
  • Net income for the latest quarter was a loss of AUD 769,000
  • Current ratio stands at 1.37, indicating solid liquidity
Acrux Limited has established itself as a key player in the biotechnology sector, focusing on hormone replacement therapies. The company's innovative products cater to a growing market, particularly for testosterone and estradiol treatments. Recent financial performance indicates a positive trajectory, with significant revenue growth and a strong gross profit margin. The ongoing expansion into international markets further positions Acrux for future growth. Despite recent losses, the company's liquidity remains robust, suggesting a stable foundation for potential investors.
AI Generated • Oct 7, 2026

Industry

Pharmaceuticals

CEO

John Warmbrunn

Headquarters

West Melbourne, VIC 3003, AU

ACR Financials

Key Financial Metrics (TTM)

Gross Margin

90.57%

Operating Margin

-46.06%

Net Income Margin

-13.01%

Return on Equity

-45.29%

Return on Capital

-53.68%

Return on Assets

-8.85%

Earnings Yield

-12.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$6.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

611.65M

Volume

752.16K

Avg. Volume

773.97K

Financials (TTM)

Gross Profit

A$3.09M

Operating Income

-A$11.69M

EBITDA

-A$10.21M

Operating Cash Flow

-A$4.24M

Capital Expenditure

-A$5.00K

Free Cash Flow

-A$4.25M

Cash & ST Invst.

A$1.71M

Total Debt

A$2.52M

Acrux Performance Analysis

Acrux annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 8,429,000390.3%
20242024-06-30AUD 5,091,000-39.6%
20252025-06-30AUD 1,190,000-76.6%
20262026-06-30AUD 4,644,000290.3%
Acrux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-82.4%
Q42025-06-30791.7%
Q22025-12-3162.6%
Q42026-06-3066.9%
Acrux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.00-92.2%
20242024-06-30AUD -0.02640.7%
20252025-06-30AUD -0.02-15.5%
20262026-06-30AUD -0.00-91.7%
Acrux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-29.5%
Q42025-06-3045.6%
Q22025-12-31106.5%
Q42026-06-30-550.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$2.90M

+325.8%

Gross Profit

A$2.69M

+535.0%

Gross Margin

92.56%

N/A

Market Cap

A$6.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$156.47K

N/A

Employees

43

N/A

Net Income

-A$769.00K

+70.0%

EBITDA

-A$632.00K

+84.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$1.71M

-42.1%

Total Debt

A$2.52M

-32.0%

Accounts Receivable

A$2.37M

-18.0%

Inventory

A$0.00

N/A

Long Term Debt

A$1.33M

-31.0%

Short Term Debt

A$1.19M

-33.1%

Return on Assets

-8.85%

N/A

Return on Invested Capital

-55.88%

N/A

Free Cash Flow

-A$510.00K

+83.5%

Operating Cash Flow

-A$510.00K

+82.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLD.AXZelira Therapeutics Limited
A$0.50+0.00%
VBS.AXVectus Biosystems Limited
A$0.11+0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%
IVX.AXInvion Limited
A$0.04-5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$6.09+57.36%
TAT&T
$23.04-6.33%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.04+0.74%
SPCXSpace Exploration Technologies
$163.11+1.58%

Questions About ACR

What is the current price of Acrux?

Acrux is trading at A$0.01 per share.

What is the 52-week range for Acrux?

Over the past 52 weeks, Acrux has traded between A$0.01 and A$0.02.

How much debt does Acrux have?

As of the most recent reporting period, Acrux reported total debt of A$2.52M.

How much cash does Acrux have on hand?

Acrux reported A$1.71M in cash and cash equivalents in its most recent financial results.

What is Acrux’s dividend yield?

Acrux does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.